Novo Nordisk says Metsera bid would accelerate drug rollout
Novo Nordisk has hit back at allegations from Pfizer that its bid for Metsera should be blocked on antitrust grounds, saying the unusual deal structure is consistent with merger law and...To view the full article, register now.
Already a subscriber? Click here to view full article